Novel targeted agents for the treatment of lung cancer in China

Cancer. 2015 Sep 1:121 Suppl 17:3089-96. doi: 10.1002/cncr.29522.

Abstract

Since the discovery of epidermal growth factor receptor mutations and epidermal growth factor receptor tyrosine kinase inhibitors, lung cancer treatment in China has entered the precision era. However, novel targeted agents based on novel biomarkers still need to be developed. In the current study, the authors review the biomarker features of lung cancer in the Chinese population and the novel agents that are aimed at novel targets. Furthermore, they discuss issues that require improvement for the production of novel drugs and provided future directions for development in China.

Keywords: China; lung cancer; novel agents; novel targets.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / epidemiology
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • China
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / genetics
  • Humans
  • Molecular Epidemiology
  • Molecular Targeted Therapy*
  • Mutation
  • Neoplasm Proteins / genetics
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Neoplasm Proteins
  • Protein Kinase Inhibitors
  • EGFR protein, human
  • ErbB Receptors